Zivo Bioscience, INC

ZIVO Bioscience will file Form 15 to suspend SEC reporting and voluntarily delist from OTC markets as part of cost cuts, with its interim CFO and a director resigning.

ZIVO Bioscience announces the immediate resignation of its CFO, Keith R. Marchiando, and the appointment of William A. Sullivan as Interim CFO.

ZIVO Bioscience's CEO highlights significant progress in human nutrition and animal health, driven by proprietary algae technology with superior antioxidant activity and immune-modulating effects.

ZIVO Bioscience announces the immediate resignation of Board Director Nola Masterson, who chaired the Nominating and Governance committee.

Zivo Bioscience, Inc. has commenced a new convertible debt offering to raise up to $2,000,000, issuing an initial bridge promissory note and accompanying warrants to an accredited investor.

ZIVO BIOSCIENCE, INC. announced that its shareholders approved all three proposals at the annual meeting held on June 9, 2025, including the election of two Class III directors, the ratification of its independent public accounting firm, and the advisory approval of executive compensation.

ZIVO Bioscience reported increased product revenue for Q3 2025, but continued to face significant operating losses and a going concern warning, necessitating further capital raises.

Zivo Bioscience reported a reduced net loss for Q2 2025 but faces substantial doubt about its ability to continue as a going concern due to critically low cash reserves.

Zivo Bioscience's Q1 2025 results reveal a significant net loss and increased R&D spending, alongside concerns about the company's ability to continue as a going concern.

Zivo Bioscience saw a revenue increase in Q3 2024 compared to the same period last year, but the company continues to operate at a loss.

Zivo Bioscience's Q2 2024 results reveal no revenue, increased operating expenses, and a net loss, alongside ongoing efforts to secure additional funding.

Zivo Bioscience reports increased revenue and reduced expenses in Q1 2024, but acknowledges ongoing concerns about its ability to continue as a going concern.

ZIVO Bioscience's 2024 10-K filing reveals increased revenue from product sales but also a substantial net loss and concerns about its ability to continue as a going concern.

Zivo Bioscience, a biotech and agtech company, reported its full year 2023 results, highlighting progress in its algal-based product development for both human and animal health.

Mark E. Strome and affiliated entities acquired 100,000 shares of Zivo Bioscience, Inc. common stock at $2.00 per share.

Zivo Bioscience Director and 10% owner Laith L. Yaldoo acquired 1,543 shares of common stock, increasing his indirect beneficial ownership.

A director and 10% owner of Zivo Bioscience, Mark E. Strome, indirectly acquired additional common stock and warrants through an affiliated entity, Strome Mezzanine Fund II, LP.

Zivo Bioscience Director Laith L. Yaldoo has filed a Form 4 indicating a planned future purchase of 2,434 shares of common stock on February 10, 2026, through HEP Investments LLC.

Zivo Bioscience Director Alison A. Cornell purchased 11,709 shares of common stock at $8.54 per share, increasing her direct beneficial ownership to 279,481 shares.

Zivo Bioscience's President and CEO, John Bernard Payne, acquired 11,709 shares of common stock at $8.54 per share, increasing his direct beneficial ownership.

Zivo Bioscience will hold its 2025 Annual Meeting of Shareholders on June 9, 2025, to vote on director elections, auditor ratification, and executive compensation.

Zivo Bioscience, Inc. has filed a definitive proxy statement with the SEC.

Zivo Bioscience announces its annual meeting of stockholders to be held on June 11, 2024, featuring proposals for director election, auditor ratification, and executive compensation approval.

Zivo Bioscience announces its 2024 Annual Meeting of Shareholders to be held on June 11, 2024, featuring proposals for director election, auditor ratification, and executive compensation approval.

Strome Mezzanine Fund II absorbed Strome Mezzanine Fund, consolidating Zivo Bioscience shares and acquiring additional stock and warrants.